Search results
Results from the WOW.Com Content Network
Persister cells are subpopulations of cells that resist treatment, and become antimicrobial tolerant by changing to a state of dormancy or quiescence. [1] [2] Persister cells in their dormancy do not divide. [3] The tolerance shown in persister cells differs from antimicrobial resistance in that the tolerance is not inherited and is reversible. [4]
Despite the copyrighted nature of the CPT code sets, the use of the code is mandated by almost all health insurance payment and information systems, including the Centers for Medicare and Medicaid Services (CMS), and the data for the code sets appears in the Federal Register. It is necessary for most users of the CPT code (principally providers ...
Lomustine is also a lipid soluble, which allows it to permeate the blood brain barrier well. This quality made it a reasonable candidate for the chemotherapy of intrinsic brain tumors. Lomustine is administered orally in six-to-eight-week intervals and with nadirs at five weeks after administration due to its delayed myelosuppressive properties ...
In TLS, the breakdown occurs after cytotoxic therapy or from cancers with high cell turnover and tumor proliferation rates. [4] The metabolic abnormalities seen in tumor lysis syndrome can ultimately result in serious complications such as acute uric acid nephropathy, acute kidney failure, seizures, cardiac arrhythmias, and death. [6] [7]
They represent items, supplies and non-physician services not covered by CPT-4 codes (Level I). Level II codes are composed of a single letter in the range A to V, followed by 4 digits. Level II codes are maintained by the US Centers for Medicare and Medicaid Services (CMS).
An illustration depicting primary tumor (in the form of tumor microenvironment) and the circulating tumor cells. A circulating tumor cell (CTC) is a cancer cell from a primary tumor that has shed into the blood of the circulatory system, or the lymph of the lymphatic system. [1]
Healthcare Common Procedure Coding System (including Current Procedural Terminology) (for outpatient use; used in United States) ICD-10 Procedure Coding System (ICD-10-PCS) (for inpatient use; used in United States) ICD-9-CM Volume 3 (subset of ICD-9-CM) (formerly used in United States prior to the introduction of the ICD-10-PCS)
For people in remission after induction chemotherapy, residual leukemic cells (minimal residual disease) are associated with higher relapse rates and decreased survival. [83] Furthermore, the presence of specific leukemic cells that are capable of initiating a relapse, the leukemia stem cell (a type of cancer stem cell ) is associated with ...